Evidence map›Paper›PMID 41130982›Full record

ArticleNature communications2025

A US case-control study to estimate infant group B streptococcal disease serological thresholds of risk-reduction.

Julia C Rhodes, Rebecca Kahn, Shanna Bolcen, Nong Shang, Yunmi Chung, Monica M Farley, Amber N Britton, Ashley E Moore, Stepy Thomas, Joelle Nadle and 28 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Maternal and Newborn Group BOpen forum infectious diseases · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

38 authors.

Julia C Rhodes *Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA. icq0@cdc.gov.ORCID http://orcid.org/0000-0003-2351-762X
Rebecca Kahn *Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Shanna BolcenDivision of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.ORCID http://orcid.org/0000-0002-7464-9967
Nong ShangDivision of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Yunmi ChungDivision of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.ORCID http://orcid.org/0000-0002-6223-8386
Monica M FarleyGeorgia Emerging Infections Program, Emory University School of Medicine, Atlanta, GA, USA.ORCID http://orcid.org/0000-0003-0557-9958
Amber N BrittonGeorgia Emerging Infections Program, Emory University School of Medicine, Atlanta, GA, USA.
Ashley E MooreGeorgia Department of Public Health, Atlanta, GA, USA.ORCID http://orcid.org/0009-0008-2438-3778
Stepy ThomasGeorgia Emerging Infections Program, Emory University School of Medicine, Atlanta, GA, USA.
Joelle NadleCalifornia Emerging Infections Program, Oakland, CA, USA.
Laura B AmsdenDivision of Research, Kaiser Permanente Northern California, Pleasanton, CA, USA.
Jacek SkarbinskiDivision of Research, Kaiser Permanente Northern California, Pleasanton, CA, USA.
Kristi R VanWindenThe Permanente Medical Group, San Leandro, California, CA, USA.ORCID http://orcid.org/0000-0003-2257-0816
Meghan BarnesColorado Department of Public Health and Environment, Denver, CO, USA.
Kerianne EngesserNew York State Department of Health, Albany, NY, USA.ORCID http://orcid.org/0009-0005-0504-9959
Patricia FerrieriUniversity of Minnesota Medical School, Minneapolis, MN, USA.
AmberJean P HansenYale School of Public Health, Connecticut Emerging Infections Program, New Haven, CT, USA.
Lee H HarrisonDepartment of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-3787-2705
Laura JeffreyDepartment of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Jessica L NyholmUniversity of Minnesota Medical School, Minneapolis, MN, USA.
Sean T O'LearyDepartment of Pediatrics, University of Colorado School of Medicine, Denver, CO, USA.
Courtney Olson-ChenUniversity of Rochester Medical Center, Rochester, NY, USA.
Jemma V RowlandsNew York State Department of Health, Albany, NY, USA.ORCID http://orcid.org/0000-0002-2320-495X
Shannon A SeopaulDepartment of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.ORCID http://orcid.org/0009-0003-4033-8727
Ann R ThomasOregon Health Authority, Portland, OR, USA.
Htet Htet N WrigleyConnecticut Department of Public Health, Hartford, CT, USA.ORCID http://orcid.org/0009-0003-9539-8831
Lesley McGeeDivision of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.ORCID http://orcid.org/0000-0001-8214-921X
Sundaram Ajay VishwanathanDivision of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.ORCID http://orcid.org/0000-0002-9157-4709
Fahmina AkhterDivision of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Bailey AlstonSeneca Federal Health, Chantilly, VA, USA.ORCID http://orcid.org/0000-0002-2239-1925
Lily Tao JiaDivision of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Yikun LiIHRC, Inc, Atlanta, GA, USA.ORCID http://orcid.org/0000-0002-2117-8057
Palak Y PatelDivision of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.ORCID http://orcid.org/0009-0004-3168-8474
Joy RiversDivision of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Jessica E SouthwellIHRC, Inc, Atlanta, GA, USA.ORCID http://orcid.org/0000-0001-9936-352X
Theresa TranDivision of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Panagiotis ManiatisDivision of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.ORCID http://orcid.org/0000-0001-5240-0848
Stephanie J SchragDivision of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA. stephanieschrag@outlook.com.ORCID http://orcid.org/0000-0002-8113-2544

Funding

Gates Foundation INV-009090
6 · The paper itself

Abstract

Maternal vaccines to prevent infant Group B Streptococcus (GBS) disease have progressed through phase II development and may be licensed based on immunologic endpoints, which have yet to be approved by regulatory authorities. Here we present a multistate case control study to characterize the relationship between serotype-specific anti-capsular polysaccharide (CPS) immunoglobulin G concentrations near birth and infant GBS disease risk reduction. Antibody concentration distributions are significantly lower for cases (n = 643) than controls (n = 2801) and serologic thresholds varied by serotype and age at onset, with 80% serotype-specific protective thresholds ranging from 0.52 to 2.49 mcg/mL for early-onset disease (EOD; <7 days old) and 0.02 to 0.14 mcg/mL for late-onset disease (LOD; 7-89 days old). Our study provides the most robust data to date that protection thresholds vary by serotype and are notably lower for LOD than EOD, thereby informing potential serological endpoints for phase III trials evaluating CPS-based maternal GBS vaccine candidates.

Indexed as

Antibodies, BacterialStreptococcal InfectionsStreptococcal VaccinesStreptococcus agalactiaeAdultCase-Control StudiesFemaleHumansImmunoglobulin GInfantInfant, NewbornMalePregnancySerogroupUnited StatesAntibodies, BacterialImmunoglobulin GStreptococcal Vaccines

Identifiers

PMID41130982
PMCPMC12549997

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.